4 recruiting, 2 unknown, 1 completed. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 4, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Tamoxifen 20 mg: new trials by email Literature Review of Tamoxifen 20 mg trials Research Report on Tamoxifen 20 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer Imlunestrant, Goserelin, Tamoxifen 20 mg - Breast Neoplasms | Phase 2 | Recruiting | Eli Lilly and Company | 600 | 2026-05-13 | 2026-10-08 |
| Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas Tamoxifen 20 mg - Pancreatic Neoplasms | Phase 2 | Recruiting | Fudan University | 30 | 2025-03-20 | 2025-04-06 |
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer Elacestrant, Triptorelin, Tamoxifen 20 mg - Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | SOLTI Breast Cancer Research Group | 96 | 2023-02-03 | 2026-04-24 |
| Therapeutic Dose Monitoring (TDM) of Tamoxifen Tamoxifen 20 mg - Breast Cancer, Breast Carcinoma | Phase 2 | Unknown | Karolinska University Hospital | 40 | 2022-04-04 | 2022-05-25 |
| Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ Tamoxifen 20 mg, Anastrozole 1Mg Tab - Ductal Carcinoma in Situ, Extensive Disease | Phase 2 | Recruiting | Institut Cancerologie de l'Ouest | 262 | 2021-02-03 | 2022-04-22 |
| Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen Tamoxifen 20 mg - Breast Cancer | Unknown | Assiut University | 100 | 2019-09-01 | 2019-07-08 | |
| A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg - Healthy | Phase 1 | Completed | Pfizer | 25 | 2013-04-01 | 2015-10-08 |
Breast Neoplasms (5) · Carcinoma, Intraductal, Noninfiltrating (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Recurrence (1)
Assiut University (1) · Eli Lilly and Company (1) · Fudan University (1) · Institut Cancerologie de l'Ouest (1) · Karolinska University Hospital (1) · Pfizer (1) · SOLTI Breast Cancer Research Group (1)
France (2) · United States (2) · Belgium (1) · China (1) · Germany (1) · Ireland (1) · Italy (1) · Spain (1) · Sweden (1) · Taiwan (1)
Amira Taha (1) · Ehab Eldesoky (1) · Elham Hedayati, MD PhD (1) · Guopei Luo Prof, MD (1) · Mohammad Hareedy (1)
2025 (1)